Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$45.57 USD

45.57
777,659

+1.27 (2.87%)

Updated Aug 27, 2024 03:59 PM ET

After-Market: $45.60 +0.03 (0.07%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tandem Diabetes Gets Canadian Nod for t:slim X2 Insulin Pump

by Zacks Equity Research

This regulatory clearance is expected to accelerate Tandem Diabetes' (TNDM) global pump shipments and expand its customer base.

Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve

by Zacks Equity Research

Tandem Diabetes (TNDM) exhibits a robust performance in the third quarter of 2019, fueled by strong domestic demand.

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) Q4 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.

DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?

by Zacks Equity Research

Growth in t:slim X2 insulin pump sales is expected to get reflected in Tandem Diabetes' (TNDM) upcoming quarterly results.

Tandem (TNDM) Catches Eye: Stock Jumps 9.5%

by Zacks Equity Research

Tandem (TNDM) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Tandem Rides on Strong t:slim X2 Rollout Amid Stiff Rivalry

by Zacks Equity Research

Tandem Diabetes (TNDM) gains on strong domestic sales along with a solid international rollout of the t:slim X2 insulin pump.

Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds

by Zacks Equity Research

Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).

Tandem Diabetes Care Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Tandem Diabetes Care has been struggling lately, but the selling pressure may be coming to an end soon.

Urmimala Biswas headshot

CGM Devices Gain Steam, Set New Trend in Diabetes Management

by Urmimala Biswas

The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.

Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ

by Zacks Equity Research

Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.

Will Tandem Diabetes Care Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Tandem Diabetes Care.

Zacks.com featured highlights include: Crocs, Skechers, Tandem, CyberArk and Fortinet

by Zacks Equity Research

Zacks.com featured highlights include: Crocs, Skechers, Tandem, CyberArk and Fortinet

Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline

by Zacks Equity Research

Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).

Sanghamitra Saha headshot

Beyond Earnings Growth: Focus on Beat With These 5 Stocks

by Sanghamitra Saha

Inside the top-ranked stocks that can beat earnings estimates in their next release.

Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.

Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country

by Zacks Equity Research

Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country

Sanghamitra Saha headshot

5 Top-Ranked Stocks Primed for an Earnings Beat

by Sanghamitra Saha

Inside the top-ranked stocks that can beat earnings estimates in their next releases.

The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center

Nalak Das headshot

5 Top Picks on Three Key Takeaways From Q2 U.S. GDP

by Nalak Das

A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.

Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?

by Zacks Equity Research

In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.

Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem Releases Positive Results Of t:slim X2 Pump Studies

by Zacks Equity Research

The results of the studies are a major breakthrough for Tandem (TNDM) in the field of diabetes treatment.

Why Is Tandem Diabetes (TNDM) Up 9.7% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.